...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.
【24h】

Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.

机译:新型修饰的雄甾烷酮类固醇衍生物作为化疗抗癌药。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study is to synthesize and evaluate new potential chemotherapeutic anti-tumor agents. Several thiazolo-, pyrido-, pyrano- and lactam steroid derivatives were obtained using 17beta-hydroxy-5alpha-androstan-3-one (androstanolone) 1 as starting steroid. The structure of the novel steroid derivatives was confirmed using the analytical and spectral data. The most pure and structurally promising compounds 7a, 10a, 12b, 18 and 23 were evaluated as anti-tumor agents. The in vitro cytotoxic activity was evaluated against hepatoma cell lines using MTT assay. Also the in vivo anti-tumor activity was evaluated against Ehrlich ascites carcinoma (EAC). The results of the in vitro study showed that at incubation time 72h, in olive oil, compound 7a was the most effective cytotoxic compound with IC(50) of 30 microM, while the effects of compounds 18 and 23 were approximately similar with IC(50) of 37 microM and 35 microM respectively. While the tested compounds when dissolved in DMSO showed approximately the same IC(50) at both 48 and 72h incubation period, compound 23 was the most effective cytotoxic with IC(50) 42 microM at 48h and 40 microM at 72h. The results of the in vivo study showed that all the tested novel compounds at 25mg/kg were effective against EAC. Our novel steroid derivatives are promising candidates as anti-cancer agents, none of the mice treated with our novel derivatives showed any toxic symptoms, but they also completely inhibited tumor growth and retained the hemoglobin content, body weight, and WBCs near normal values and similar to what obtained for the standard drug 5-flurouracil.
机译:本研究的目的是合成和评估新的潜在的化疗抗肿瘤药物。使用17β-羟基-5α-雄烷-3-酮(雄甾烷酮)1作为起始类固醇,可获得几种噻唑基,吡啶基,吡喃基和内酰胺类固醇衍生物。使用分析和光谱数据证实了新型类固醇衍生物的结构。评价了最纯净且结构上最有希望的化合物7a,10a,12b,18和23作为抗肿瘤剂。使用MTT测定法评估了针对肝癌细胞系的体外细胞毒性活性。还评估了针对艾氏腹水癌(EAC)的体内抗肿瘤活性。体外研究结果表明,在橄榄油中孵育72h时,化合物7a是最有效的细胞毒性化合物,IC(50)为30 microM,而化合物18和23的作用与IC(50)大致相似分别为37 microM和35 microM。当测试化合物溶于DMSO时,在48和72h的孵育期显示出大致相同的IC(50),而化合物23对IC(50)的作用最有效,在48h时为42 microM,在72h时为40 microM。体内研究结果表明,所有测试的25mg / kg新型化合物均能有效对抗EAC。我们的新型类固醇衍生物有望作为抗癌药候选,用我们的新型衍生物治疗的小鼠均未显示任何毒性症状,但它们也完全抑制了肿瘤的生长,并保持血红蛋白含量,体重和白细胞接近正常值或类似水平。达到标准药物5-氟尿嘧啶的水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号